loading
Biocryst Pharmaceuticals Inc stock is traded at $7.30, with a volume of 1.58M. It is up +1.25% in the last 24 hours and down -4.20% over the past month. BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$7.21
Open:
$7.16
24h Volume:
1.58M
Relative Volume:
0.83
Market Cap:
$1.51B
Revenue:
$331.41M
Net Income/Loss:
$-226.54M
P/E Ratio:
-5.84
EPS:
-1.25
Net Cash Flow:
$-97.31M
1W Performance:
-4.45%
1M Performance:
-4.20%
6M Performance:
+19.09%
1Y Performance:
+35.19%
1-Day Range:
Value
$7.0905
$7.505
1-Week Range:
Value
$6.92
$7.74
52-Week Range:
Value
$4.03
$8.88

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Name
Name
Biocryst Pharmaceuticals Inc
Name
Phone
919-859-1302
Name
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Name
Employee
531
Name
Twitter
@biocrystpharma
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
BCRX's Discussions on Twitter

Compare BCRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
BCRX 7.30 1.51B 331.41M -226.54M -97.31M -1.25
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-18-23 Upgrade RBC Capital Mkts Sector Perform → Outperform
Aug-04-23 Upgrade Jefferies Hold → Buy
Jul-13-23 Upgrade BofA Securities Neutral → Buy
Feb-22-23 Upgrade Needham Hold → Buy
Nov-02-22 Upgrade Evercore ISI In-line → Outperform
Aug-05-22 Downgrade Evercore ISI Outperform → In-line
Aug-05-22 Downgrade Oppenheimer Outperform → Perform
Apr-18-22 Downgrade Barclays Overweight → Equal Weight
Apr-11-22 Downgrade BofA Securities Buy → Neutral
Dec-10-21 Initiated Oppenheimer Outperform
Aug-06-21 Downgrade Jefferies Buy → Hold
Aug-03-21 Initiated Cantor Fitzgerald Overweight
Mar-01-21 Initiated Cowen Outperform
Sep-29-20 Resumed JP Morgan Overweight
Jun-17-20 Initiated BTIG Research Neutral
May-05-20 Upgrade Barclays Equal Weight → Overweight
Nov-15-19 Upgrade BofA/Merrill Neutral → Buy
May-24-19 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-16-18 Resumed Piper Jaffray Overweight
Aug-08-18 Resumed JP Morgan Overweight
Jul-17-18 Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18 Initiated Seaport Global Securities Neutral
Jan-02-18 Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-20-17 Initiated Barclays Equal Weight
Sep-15-17 Initiated RBC Capital Mkts Sector Perform
Sep-06-17 Upgrade JP Morgan Neutral → Overweight
Sep-06-17 Upgrade Jefferies Hold → Buy
Feb-16-17 Initiated Ladenburg Thalmann Buy
Aug-12-16 Upgrade Piper Jaffray Neutral → Overweight
Aug-04-16 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16 Reiterated FBR Capital Outperform
Feb-09-16 Downgrade JP Morgan Overweight → Neutral
Feb-09-16 Downgrade Needham Buy → Hold
View All

Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News

pulisher
Nov 20, 2024

Cystinosis Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR

Nov 20, 2024
pulisher
Nov 19, 2024

Counterweight Ventures LLC Increases Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Primary Hyperoxaluria Drug Market SWOT Analysis by Leading Key Players: Pfizer, Novartis, BioCryst - openPR

Nov 18, 2024
pulisher
Nov 18, 2024

Short Interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Decreases By 7.5% - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

BioCryst Launches ORLADEYO® (berotralstat) in Ireland - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

BioCryst's ORLADEYO Becomes First Oral HAE Treatment Approved in Ireland | BCRX Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 17, 2024

(BCRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Nov 17, 2024
pulisher
Nov 13, 2024

Avian influenza Treatment Market Growth Trends: Regional - openPR

Nov 13, 2024
pulisher
Nov 12, 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by GSA Capital Partners LLP - MarketBeat

Nov 12, 2024
pulisher
Nov 09, 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Nov 09, 2024
pulisher
Nov 07, 2024

Vanguard Group Inc's Strategic Acquisition in BioCryst Pharmaceu - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

HC Wainwright Has Optimistic Outlook of BCRX Q4 Earnings - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Ionis Looks Ahead To Commercializing Its Own Products - Citeline News & Insights

Nov 06, 2024
pulisher
Nov 06, 2024

Objective long/short (BCRX) Report - Stock Traders Daily

Nov 06, 2024
pulisher
Nov 06, 2024

BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire

Nov 06, 2024
pulisher
Nov 06, 2024

BioCryst (BCRX) to Present at Three Major Healthcare Investor Conferences | BCRX Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Earnings Results, Hits Estimates - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

BioCryst Pharmaceuticals' (BCRX) "Outperform" Rating Reiterated at Royal Bank of Canada - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Barclays Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

BCRXBioCryst Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Earnings call: BioCryst Pharmaceuticals reports strong Q3 growth - Investing.com India

Nov 05, 2024
pulisher
Nov 05, 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 05, 2024
pulisher
Nov 05, 2024

BioCryst Announces Strong Q3 2024 Revenue Growth - Yahoo Finance

Nov 05, 2024
pulisher
Nov 05, 2024

BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

BioCryst Awards Key Talent with $8.01 Stock Options, RSU Compensation Package | BCRX Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

Nov 05, 2024
pulisher
Nov 05, 2024

BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highli - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ... - Yahoo Finance

Nov 05, 2024
pulisher
Nov 05, 2024

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 05, 2024
pulisher
Nov 04, 2024

Earnings call: BioCryst Pharmaceuticals reports strong Q3 growth By Investing.com - Investing.com Australia

Nov 04, 2024
pulisher
Nov 04, 2024

BioCryst: Q3 Earnings Snapshot - Darien Times

Nov 04, 2024
pulisher
Nov 04, 2024

BioCryst shares hold Buy rating, BofA sees entry point By Investing.com - Investing.com Canada

Nov 04, 2024
pulisher
Nov 04, 2024

Piper Sandler lifts BioCryst Pharma target to $21 on Q3 beat - Investing.com UK

Nov 04, 2024
pulisher
Nov 04, 2024

BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript - AOL

Nov 04, 2024
pulisher
Nov 04, 2024

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap DownHere's Why - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 04, 2024
pulisher
Nov 04, 2024

BioCryst Pharmaceuticals Q3 2024 Earnings: EPS Loss of $0.07, Re - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 04, 2024
pulisher
Nov 02, 2024

BioCryst Pharmaceuticals Q3 2024 Earnings Preview - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Rice Hall James & Associates LLC - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

‘Breakthrough’ quarter for Island Pharmaceuticals - The Mercury

Oct 31, 2024
pulisher
Oct 31, 2024

Island Pharmaceuticals enjoys big quarter - Courier Mail

Oct 31, 2024
pulisher
Oct 28, 2024

Semanteon Capital Management LP Invests $1.14 Million in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

BioCryst Pharmaceuticals (BCRX) Scheduled to Post Earnings on Monday - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

When (BCRX) Moves Investors should Listen - Stock Traders Daily

Oct 26, 2024
pulisher
Oct 25, 2024

How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5% - MSN

Oct 25, 2024
pulisher
Oct 24, 2024

What's Going On With BioCryst Pharmaceuticals Stock? - MSN

Oct 24, 2024
pulisher
Oct 24, 2024

BioCryst Presents New Real-World Evidence Showing High - GlobeNewswire

Oct 24, 2024
pulisher
Oct 24, 2024

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat) - StockTitan

Oct 24, 2024
pulisher
Oct 23, 2024

High Growth Tech Stocks To Watch In October 2024 - Simply Wall St

Oct 23, 2024

Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):